lercanidipine / Generic mfg. - LARVOL DELTA

QbD-driven RP-HPLC method for the simultaneous analysis of dihydropyridines calcium channel blockers in pharmaceuticals. (PubMed, BMC Chem) - "A rapid, sensitive, and selective reversed-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous determination of five dihydropyridines calcium channel blockers, namely: amlodipine (AML), nifedipine (NIF), lercanidipine (LER), nimodipine (NIM) and nitrendipine (NIT) using Quality by Design approaches (QbD). The validated method was successfully applied for the determination of these drugs in their pharmaceutical formulations, with recovery values ranging from 99.57 to 100.07% and without significant interference from excipients. Greenness and practicality evaluations detected using AGREE, MoGAPI, complex MoGAPI, AGSA, CaFRI, BAGI and CACI tools which were, indicating the method's environmental friendliness and excellent practical applicability for routine pharmaceutical quality control analysis."

Journal • Acute Myelogenous Leukemia

Evaluation the inhibitory effect of nicardipine on the metabolism of quetiapine. (PubMed, Front Pharmacol) - "In vitro, two incubation systems of rat liver microsomes (RLM) and human liver microsomes (HLM) were established and optimized to explore potential interactions between five kinds CCBs (nicardipine, dilthiazem, lercanidipine, nimodipine, nitrendipine), five kinds antihypertensive TCM (quercetin, fangchinoline, apigenin, tetrandrine, and berberine) and quetiapine, and to evaluate their underlying inhibition mechanisms. In vivo results indicated that nicardipine could significantly increase the main pharmacokinetic parameters AUC(0-t), , and Cmax of quetiapine, but decrease the AUC(0-t) of its metabolite N-desalkylquetiapine. The findings of this study suggested that nicardipine had inhibited the metabolism of quetiapine, suggesting the dose adjustment or therapeutic drug monitoring of quetiapine should be conducted to achieve individualized therapy."

Journal

Cytogenotoxic Evaluation of Lercanidipine Hydrochloride in Human Lymphocytes Using Micronucleus, Chromosome Abnormalities, and Molecular Docking Assays. (PubMed, Cell Biol Int) - "By contrast, the positive control, mitomycin C (MMC), binds to the major groove via intercalation, forming covalent cross-links, with a binding energy of -5.45 kcal/mol. Overall, these findings suggest that LHC primarily exhibits cytotoxic effects (e.g., inhibition of DNA replication or transcription), with only limited and preliminary evidence of genotoxic potential. Further studies are needed to elucidate the safety of LHC and its DNA interaction mechanisms."

Journal • Oncology

Case-based evaluation of a digital timeline tool for drug causality assessment in skin eruptions (EADV 2025) - " The digital timeline identified five drugs with temporally compatible exposure: rilmenidine, diosmectite, enoxaparin, lercanidipine, and the combination perindopril/indapamide. This case highlights the potential benefit of digital tools in standardizing the visualization of medication histories for suspected drug-induced skin reactions. Digitalization of causality assessment processes may enhance diagnostic accuracy and workflow efficiency in complex clinical scenarios."

Clinical • Immunology

Drug-Induced Cutaneous Vasculitis: A Report of Three Cases (EADV 2025) - "Case2 A 44-year-old man, hospitalized for an ankle fracture, developed palpable purpura on his upper and lower limbs seven days after starting cefotaxime and ciprofloxacin...The implicated agents—lercanidipine, cephalosporins, fluoroquinolones, adalimumab—illustrate the wide pharmacologic range of potential triggers. In any recent-onset cutaneous vasculitis, drug-induced causes should be systematically considered and assessed through clinical evolution after withdrawal of the suspected agent."

Clinical • Acute Kidney Injury • Cardiovascular • Crohn's disease • Diabetes • Endocrine Disorders • Eosinophilia • Fibrosis • Gastroenterology • Hypertension • Infectious Disease • Inflammatory Bowel Disease • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Renal Disease • Vasculitis

Beta-blocker side-effects in clinical practice: a nationwide approach (ESC-WCC 2025) - "The predominantly prescribed BBs were metoprolol (76%), propranolol (7%), carvedilol (6%), and bisoprolol (6%), whereas amlodipine (84%) and lercanidipine (11%) constituted the majority of the CCB group. (Figure 2) Conclusions In a large nationwide cohort, the incidence of BB side-effects was clinically relevant and consistently increased compared with CCBs with the exception of erectile dysfunction. These findings are exceptionally clinically relevant and surprising as erectile dysfunction is often the most prevalent concern for male patients when initiating BB treatment."

Adverse events • Clinical • Cardiovascular • Hypertension

Choosing the right calcium channel blocker for patients with hypertension and proteinuric chronic kidney disease. (PubMed, Curr Med Res Opin) - "In the present narrative review, we aimed to specifically describe the cardiorenal protective effects of dihydropyridine CCBs (particularly lercanidipine and manidipine, based on the available evidence) and non-dihydropyridine CCBs (verapamil and diltiazem). With regard to this research topic, we also reviewed the 2023 European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension [endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)] and the 2023 European Society of Cardiology (ESC) Guidelines for the management of cardiomyopathies. Finally, we proposed practical criteria for prescribing the most appropriate CCB (among dihydropyridine CCBs and non-dihydropyridine CCBs) for patients with hypertension and proteinuric CKD (with or without diabetes) in different clinical settings."

Journal • Review • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

Lercanidipine-Induced Hyponatremia in Elderly Patients: A Not-So-Rare Complication. (PubMed, Cureus) - "Current NHS guidelines do not recommend routine electrolyte monitoring when prescribing CCBs, unlike recommendations for ACE inhibitors and ARBs. We recommend implementing routine electrolyte monitoring when initiating CCBs in this vulnerable population group to prevent potentially life-threatening complications."

Journal • Cardiovascular • Critical care • Geriatric Disorders • Heart Failure • Hypertension

SKIN-CKD: The Role of Skin Sodium Accumulation in Chronic Kidney Disease (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

New trial • Chronic Kidney Disease • Nephrology • Renal Disease

Management of Lercanidipine-induced Lyell's syndrome (Euroanaesthesia 2025) - "Pain was managed with patient-controlled analgesia of Morphine, Ketamine and Droperidol plus peripheral analgesia. Hydrotherapy sessions were provided with a combination of Propofol, Ketamine, Dexmedetomidine, and Fentanyl, allowing effective wound care.Patient care involved daily ophthalmology evaluation, pulmonary rehabilitation and oxygen therapy. By the 24th day of hospitalization, the patient showed over 90% healing of the affected skin areas and was discharged home. This case underscores the critical importance of intensive and rigorous care in the management of TEN, particularly in a specialized BU. Rapid disease progression shows the unpredictable nature of this severe drug-induced reaction."

Inflammation • Ophthalmology • Pain • Rare Diseases • Steven-Johnson Syndrome

Lercanidipine Enhances Cisplatin Activity: Dual Anticancer and Anti-Inflammatory Effects via Caspase Activation and MAPK Inhibition. (PubMed, Pharmaceuticals (Basel)) - "It also significantly inhibited MAPK signaling, activated apoptotic caspases, and reduced TNF-α levels, suggesting potential anti-inflammatory activity. These findings highlight lercanidipine's potential for repurposing as an adjunct in cancer therapy."

Journal • Breast Cancer • Cardiovascular • Genito-urinary Cancer • Neuroblastoma • Oncology • Prostate Cancer • Solid Tumor • CASP3 • CASP8 • TNFA

Nonsurgical management of pheochromocytoma in the very elderly – a case series and review of the literature (ESPE-ESE 2025) - "Blood pressure (BP) treatment was with doxazosin, losartan and bisoprolol...On a follow up of 0.54 years BP was slightly elevated and was controlled with doxazosin, lercanidipine and bisoprolol... in this series of three elderly patients with PCC that did not have an adrenalectomy we found one occurrence of a stroke and one death in the same patient on an average follow up of 5.69 years. It thus seems that medical management may allow satisfactory disease control in select cases in which surgery is not possible or refused by very elderly patients."

Clinical • Review • Cardiovascular • Endocrine Cancer • Oncology • Solid Tumor

Warning issued over common blood pressure drug after labelling error (MSN News) - "Patients who take a common drug for high blood pressure are being urged to check the medication after its manufacturer reported that a mistake in the strength of the dose had been printed on some packs...One batch of the medicine Lercanidipine, made by Recordati Pharmaceuticals, is labelled as containing 10mg tablets when it in fact contains 20mg....The correct strength is printed on the top of the carton and on the blister strips, according to an alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA)...Patients are being urged to check for the batch number MD4L07 with an expiry date of January 2028 as a 'precautionary measure'."

Commercial • Hypertension

Voltammetric determination of lercanidipine in urine, blood plasma, and serum using hollow fiber-based liquid phase microextraction. (PubMed, Talanta) - "The calibration dependence of the combined HF-LPME-SWV method was established in the range of 1-1000 nmol L-1, with limits of quantification (LOQ) and detection (LOD) of 3.3 and 1.1 nmol L-1, respectively. The applicability of the developed method was verified by analysis of human urine, blood plasma, and blood serum samples spiked with 20 and 100 nmol L-1 LCN with recoveries ranging from 93.2 to 112.9 % with respective RSDs 1.72-8.5 % (n = 3)."

Journal

Looks are deceiving: An uncommon cause of milky white peritoneal dialysis effluent. (PubMed, Perit Dial Int) - "We suspended lercanidipine and within a few days the peritoneal dialysis effluent was clear. Currently the patient is well adjusted to the technique and had no further episodes of chyloperitoneum."

Journal • Dyslipidemia • Hypertriglyceridemia

UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma. (PubMed, Biomed Pharmacother) - "Drug concentrations in the patient's serum or urine (also known as therapeutic drug monitoring, or TDM) and blood pressure measurements following supervised medication ingestion are two techniques for assessing treatment adherence. In alignment with guideline from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), this study aims to design, develop, and validate a single UHPLC method for the plasma quantification of five antihypertensive drugs within the calcium channel blocker class: amlodipine, nifedipine, barnidipine, lercanidipine and lacidipine."

Journal • Cardiovascular • Hypertension

Comparative Effectiveness of Lercanidipine and Amlodipine on Major Adverse Cardiovascular Events in Hypertensive Patients. (PubMed, Am J Hypertens) - "Lercanidipine demonstrated comparable effectiveness to amlodipine in preventing MACE among hypertensive patients. Given its comparable antihypertensive efficacy and potential for fewer side effects based on prior studies, lercanidipine may be considered a preferable option for hypertension management."

Adverse events • HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Myocardial Infarction

SHARK PEDICLE ISLAND FLAP FOR BASAL CELL CARCINOMA OF THE PERIALAR ZONE OF THE NOSE: PHOTOXICITY AND PHOTOCARCINOGENICITY MEDIATED BY POTENTIALLY NITROSAMINE CONTAMINATED DRUG INTAKE -A NEW EXPLANATION FOR THE SKIN CANCERS PATHOGENESIS? (PubMed, Georgian Med News) - "We inform about another polymedication intake in a patient with arterial hypertension and diabetes mellitus, which includes the following medications: gliclazide 60 mg once daily and metformin hydrochloride 850 mg once daily, both since 24 years ; sotalol hydrochloride 80 mg since 2 years; bisoprolol fumarate 5 mg since 17 years; candesartan cilexetil/hydrochlorothiazide 16 mg/ 12.5 mg since 2 years; and lercanidipine hydrochloride 20 mg also since 2 years. An optimal postoperative outcome was achieved. This article focuses on the possible role of drug-mediated photo nitrosogenesis/ carcinogenesis of skin cancer by briefly reviewing and analyzing the available literature to date."

Journal • Basal Cell Carcinoma • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Metabolic Disorders • Non-melanoma Skin Cancer • Oncology • Pulmonary Arterial Hypertension • Skin Cancer

Annular elastolytic giant cell granuloma: Lesions in non-sun exposed areas, treated with topical dapson, alongside topical steroids (EADV 2024) - "The patient ’ s medication history revealed metoprolol, doxazosin, lercanidipine and apixaban...The first biopsy showed urticarial reaction but the patient did not respond to bilastine 20mg/day...Afterwards, we changed the therapy to topical clobetasol propionate lotion %0.05, 2x1 on weekdays and topical dapson %7.5, 1x1, every day, and achieved nearly %90 remission in 4 months (second cycle of therapy)... To conclude, AECGC may be seen in non-sun-exposed areas, and if the suspicion of AEGCG is not indicated to the pathologist in advance, the diagnosis may be overlooked. And topical dapson therapy may be an option in the treatment of the disease, but further research is needed."

Atrial Fibrillation • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Monoclonal Gammopathy • Rare Diseases • Urticaria • Vasculitis

Calcium channel blocker overdose: Not all the same toxicity. (PubMed, Br J Clin Pharmacol) - "Dihydropyridines were the commonest CCB overdoses, with amlodipine making up half. More severe toxicity occurred with diltiazem and verapamil."

Journal • Acute Kidney Injury • Critical care • Hypotension • Nephrology • Renal Disease

Unveiling the Preparation and Characterization of Lercanidipine Hydrochloride in an Oral Solid Self-Nanoemulsion for Enhancing Oral Delivery. (PubMed, Cureus) - "This study successfully prepared LRCH using the promising strategy of SSNEDDS as a hard gelatin capsule with a higher dispersion rate. It improved its stability and expected bioavailability compared to the brand-marketed tablet as the standard."

Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Anti-inflammatory efficacy of lercanidipine hydrochloride on TNF-α induced HaCaT cells and TPA-induced acute mouse ear inflammation model. (PubMed, Arch Dermatol Res) - No abstract available

Journal • Preclinical • Inflammation • TNFA

Toxicologic analysis of 35 drugs in post mortem human blood samples with focus on antihypertensive and antiarrhythmic drugs. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "Therefore, a novel analytical method was developed and validated for the quantification of 35 drugs with toxicological relevance, including antihypertensive and antiarrhythmic drugs (ajmaline, amlodipine, amiodarone, atenolol, bisoprolol, carvedilol, clonidine, desethylamiodarone, diltiazem, donepezil, doxazosin, dronedarone, esmolol, flecainide, lercanidipine, lidocaine, metoprolol, nebivolol, nimodipine, pindolol, prajmaline, propafenone, propranolol, sotalol, urapidil, and verapamil), as well as other medications commonly found in combination (sildenafil, tadalafil, atorvastatin, clopidogrel, dapoxetine, memantine, pentoxifylline, rivastigmine, and ivabradine). In addition, the method was specifically tested for the use in post mortem analysis. The applicability of our method was demonstrated by the analysis of two authentic human autopsy blood samples."

Journal

A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities. (PubMed, Diab Vasc Dis Res) - "In this cohort, with 50% diabetes prevalence, pancreatic, stomach, lung and bronchus, and ovarian cancers were strongly associated with VTE. Corticosteroids, gabapentinoids, and psychotropic medications had the strongest associations with VTE among medications. This may be valuable for generating hypotheses for the further research. Lercanidipine may be a novel protective medication against VTE."

Journal • Cardiovascular • CNS Disorders • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammatory Bowel Disease • Mental Retardation • Metabolic Disorders • Oncology • Ovarian Cancer • Pancreatic Cancer • Psychiatry • Respiratory Diseases • Solid Tumor • Venous Thromboembolism

Calcium-channel blockers chyloperitoneum: an underrated complication in peritoneal dialysis (ERA-EDTA 2024) - "All of them were affected by hypertension and 10 of 16 (2 APD and 8 CAPD) were already in chronic therapy with CCBs (5 with lercanidipine, 4 with lacidipine and 1 with barnidipine), all at maximum accepted dosage. cloudy peritoneal effluent is always cause for concern for Nephrologists since that it could represent, event without any other sign or symptom of infection, an already subclinical bacterial peritonitis. Most of dialysis patients are also affected by hypertension. Since usage of ARB and ACE-I is limited by risk of hyperkalaemia, CCBs represents one of the most prescribed antihypertensive drugs."

Cardiovascular • Hypertension • Infectious Disease • Nephrology • Pain • Pancreatitis